Multiple diseases in carrier probability estimation: Accounting for surviving all cancers other than breast and ovary in BRCAPRO

Hormuzd A. Katki, Amanda Blackford, Sining Chen, Giovanni Parmigiani

Research output: Contribution to journalArticle

Abstract

Mendelian models can predict who carries an inherited deleterious mutation of known disease genes based on family history. For example, the BRCAPRO model is commonly used to identify families who carry mutations of BRCA1 and BRCA2, based on familial breast and ovarian cancers. These models incorporate the age of diagnosis of diseases in relatives and current age or age of death. We develop a rigorous foundation for handling multiple diseases with censoring. We prove that any disease unrelated to mutations can be excluded from the model, unless it is sufficiently common and dependent on a mutation-related disease time. Furthermore, if a family member has a disease with higher probability density among mutation carriers, but the model does not account for it, then the carrier probability is deflated. However, even if a family only has diseases the model accounts for, if the model excludes a mutation-related disease, then the carrier probability will be inflated. In light of these results, we extend BRCAPRO to account for surviving all non-breast/ovary cancers as a single outcome. The extension also enables BRCAPRO to extract more useful information from male relatives. Using 1500 families from the Cancer Genetics Network, accounting for surviving other cancers improves BRCAPRO's concordance index from 0.758 to 0.762 (p=0.046), improves its positive predictive value from 35 to 39 per cent (p-6) without impacting its negative predictive value, and improves its overall calibration, although calibration slightly worsens for those with carrier probability

Original languageEnglish (US)
Pages (from-to)4532-4548
Number of pages17
JournalStatistics in Medicine
Volume27
Issue number22
DOIs
StatePublished - Sep 30 2008

Fingerprint

Ovary
Ovarian Neoplasms
Cancer
Breast Neoplasms
Mutation
Calibration
Model
Ovarian Cancer
Genetic Network
Concordance
Censoring
Probability Density
Breast Cancer
Neoplasms
Family
Gene
Predict
Dependent

Keywords

  • BRCA1
  • BRCA2
  • Competing risks
  • Mendelian models
  • Mendelian mutation prediction models
  • MMRpro
  • Risk assessment

ASJC Scopus subject areas

  • Epidemiology
  • Statistics and Probability

Cite this

Multiple diseases in carrier probability estimation : Accounting for surviving all cancers other than breast and ovary in BRCAPRO. / Katki, Hormuzd A.; Blackford, Amanda; Chen, Sining; Parmigiani, Giovanni.

In: Statistics in Medicine, Vol. 27, No. 22, 30.09.2008, p. 4532-4548.

Research output: Contribution to journalArticle

Katki, Hormuzd A. ; Blackford, Amanda ; Chen, Sining ; Parmigiani, Giovanni. / Multiple diseases in carrier probability estimation : Accounting for surviving all cancers other than breast and ovary in BRCAPRO. In: Statistics in Medicine. 2008 ; Vol. 27, No. 22. pp. 4532-4548.
@article{32493f423b9140ebb7a712f2bfcf4faa,
title = "Multiple diseases in carrier probability estimation: Accounting for surviving all cancers other than breast and ovary in BRCAPRO",
abstract = "Mendelian models can predict who carries an inherited deleterious mutation of known disease genes based on family history. For example, the BRCAPRO model is commonly used to identify families who carry mutations of BRCA1 and BRCA2, based on familial breast and ovarian cancers. These models incorporate the age of diagnosis of diseases in relatives and current age or age of death. We develop a rigorous foundation for handling multiple diseases with censoring. We prove that any disease unrelated to mutations can be excluded from the model, unless it is sufficiently common and dependent on a mutation-related disease time. Furthermore, if a family member has a disease with higher probability density among mutation carriers, but the model does not account for it, then the carrier probability is deflated. However, even if a family only has diseases the model accounts for, if the model excludes a mutation-related disease, then the carrier probability will be inflated. In light of these results, we extend BRCAPRO to account for surviving all non-breast/ovary cancers as a single outcome. The extension also enables BRCAPRO to extract more useful information from male relatives. Using 1500 families from the Cancer Genetics Network, accounting for surviving other cancers improves BRCAPRO's concordance index from 0.758 to 0.762 (p=0.046), improves its positive predictive value from 35 to 39 per cent (p-6) without impacting its negative predictive value, and improves its overall calibration, although calibration slightly worsens for those with carrier probability",
keywords = "BRCA1, BRCA2, Competing risks, Mendelian models, Mendelian mutation prediction models, MMRpro, Risk assessment",
author = "Katki, {Hormuzd A.} and Amanda Blackford and Sining Chen and Giovanni Parmigiani",
year = "2008",
month = "9",
day = "30",
doi = "10.1002/sim.3302",
language = "English (US)",
volume = "27",
pages = "4532--4548",
journal = "Statistics in Medicine",
issn = "0277-6715",
publisher = "John Wiley and Sons Ltd",
number = "22",

}

TY - JOUR

T1 - Multiple diseases in carrier probability estimation

T2 - Accounting for surviving all cancers other than breast and ovary in BRCAPRO

AU - Katki, Hormuzd A.

AU - Blackford, Amanda

AU - Chen, Sining

AU - Parmigiani, Giovanni

PY - 2008/9/30

Y1 - 2008/9/30

N2 - Mendelian models can predict who carries an inherited deleterious mutation of known disease genes based on family history. For example, the BRCAPRO model is commonly used to identify families who carry mutations of BRCA1 and BRCA2, based on familial breast and ovarian cancers. These models incorporate the age of diagnosis of diseases in relatives and current age or age of death. We develop a rigorous foundation for handling multiple diseases with censoring. We prove that any disease unrelated to mutations can be excluded from the model, unless it is sufficiently common and dependent on a mutation-related disease time. Furthermore, if a family member has a disease with higher probability density among mutation carriers, but the model does not account for it, then the carrier probability is deflated. However, even if a family only has diseases the model accounts for, if the model excludes a mutation-related disease, then the carrier probability will be inflated. In light of these results, we extend BRCAPRO to account for surviving all non-breast/ovary cancers as a single outcome. The extension also enables BRCAPRO to extract more useful information from male relatives. Using 1500 families from the Cancer Genetics Network, accounting for surviving other cancers improves BRCAPRO's concordance index from 0.758 to 0.762 (p=0.046), improves its positive predictive value from 35 to 39 per cent (p-6) without impacting its negative predictive value, and improves its overall calibration, although calibration slightly worsens for those with carrier probability

AB - Mendelian models can predict who carries an inherited deleterious mutation of known disease genes based on family history. For example, the BRCAPRO model is commonly used to identify families who carry mutations of BRCA1 and BRCA2, based on familial breast and ovarian cancers. These models incorporate the age of diagnosis of diseases in relatives and current age or age of death. We develop a rigorous foundation for handling multiple diseases with censoring. We prove that any disease unrelated to mutations can be excluded from the model, unless it is sufficiently common and dependent on a mutation-related disease time. Furthermore, if a family member has a disease with higher probability density among mutation carriers, but the model does not account for it, then the carrier probability is deflated. However, even if a family only has diseases the model accounts for, if the model excludes a mutation-related disease, then the carrier probability will be inflated. In light of these results, we extend BRCAPRO to account for surviving all non-breast/ovary cancers as a single outcome. The extension also enables BRCAPRO to extract more useful information from male relatives. Using 1500 families from the Cancer Genetics Network, accounting for surviving other cancers improves BRCAPRO's concordance index from 0.758 to 0.762 (p=0.046), improves its positive predictive value from 35 to 39 per cent (p-6) without impacting its negative predictive value, and improves its overall calibration, although calibration slightly worsens for those with carrier probability

KW - BRCA1

KW - BRCA2

KW - Competing risks

KW - Mendelian models

KW - Mendelian mutation prediction models

KW - MMRpro

KW - Risk assessment

UR - http://www.scopus.com/inward/record.url?scp=53349172236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53349172236&partnerID=8YFLogxK

U2 - 10.1002/sim.3302

DO - 10.1002/sim.3302

M3 - Article

C2 - 18407567

AN - SCOPUS:53349172236

VL - 27

SP - 4532

EP - 4548

JO - Statistics in Medicine

JF - Statistics in Medicine

SN - 0277-6715

IS - 22

ER -